每周卡铂同步放疗治疗宫颈癌的疗效:一项Meta分析
该Meta分析纳入12项前瞻性和回顾性研究共1698例宫颈癌患者,比较每周卡铂同步放化疗(Car-RT)与顺铂同步放化疗(Cis-RT)的疗效。Car-RT的完全缓解率较低(OR 0.53,95%CI 0.34-0.82),3年无进展生存/无病生存和3年总生存有劣于Cis-RT的趋势。Car-RT组≥3级急性毒性事件不常见,作者认为卡铂是顺铂禁忌患者的合适同步药物。
要点
- 与Cis-RT相比,Car-RT的完全缓解率较低(OR 0.53,95%CI 0.34-0.82,I²=0%)。
- Car-RT较Cis-RT的3年PFS/DFS(OR 0.71,95%CI 0.49-1.02)和3年OS(OR 0.70,95%CI 0.46-1.05)有更差的趋势。
- Car-RT组≥3级急性毒性事件不常见,卡铂可用于顺铂禁忌患者。
核心结论
- 在宫颈癌治疗中,Car-RT较Cis-RT显示较差的肿瘤缓解和更差的生存趋势,但证据受研究间不平衡的限制。
- 由于疗效令人鼓舞且毒性低,卡铂是顺铂禁忌患者的合适同步药物。
研究设计与样本
- 研究为Meta分析,纳入前瞻性和回顾性研究,共12项研究、1698例患者。
- 主要终点为完全缓解率、无进展生存/无病生存和总生存,报告为比值比(OR)和95%置信区间(CI)。
- 合并估计了Car-RT组的完全缓解率和生存率,并总结了急性毒性。
主要发现
- Car-RT组与Cis-RT组相比,完全缓解率较低(OR 0.53;95%CI 0.34-0.82,I²=0%)。
- Car-RT组与Cis-RT组相比,3年PFS/DFS有更差的趋势(OR 0.71;95%CI 0.49-1.02,I²=0%)。
- Car-RT组与Cis-RT组相比,3年OS有更差的趋势(OR 0.70;95%CI 0.46-1.05,I²=36%)。
- Car-RT组的合并总体完全缓解率为81%(95%CI 0.74-0.89)。
- Car-RT组的合并3年PFS/DFS率为64%(95%CI 0.52-0.78),合并3年OS率为73%(95%CI 0.62-0.87)。
临床怎么用
- 作者认为,由于疗效令人鼓舞且毒性低,卡铂是顺铂禁忌患者的合适同步药物。
局限性
- 证据受研究间不平衡的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to evaluate whether carboplatin has a comparable efficacy with cisplatin as part of weekly concurrent chemoradiotherapy for cervical cancer (Car-RT vs. Cis-RT). METHODS: A literature search was conducted and both prospective and retrospective studies that evaluated the efficacy of Car-RT for cervical cancer were included. The primary endpoints were complete response (CR) rate, progression-free survival (PFS)/disease-free survival (DFS), overall survival (OS), reported as odds ratios (ORs) and 95% confidence intervals (CIs). The estimated CR rate and survival of patients treated with Car-RT were pooled. Acute toxicity was also summarized. RESULTS: Twelve studies consisting of 1698 patients were eligible for meta-analysis. A lower CR rate (OR, 0.53; 95% CI, 0.34-0.82, I2 = 0%) and a trend toward poorer 3-year PFS/DFS (OR, 0.71; 95% CI, 0.49-1.02, I2 = 0%) and 3-year OS (OR, 0.70; 95% CI, 0.46-1.05, I2 = 36%) were found in Car-RT compared with Cis-RT. For the Car-RT groups, the pooled overall CR rate was 81% (95% CI 0.74-0.89). The pooled 3-year PFS/DFS rate was 64% (95% CI 0.52-0.78). The pooled 3-year OS rate was 73% (95% CI 0.62-0.87). Acute toxic events ≥ grade 3 were infrequent in the Car-RT groups. CONCLUSIONS: Car-RT showed a poorer tumor response and a trend toward inferior survival compared with Cis-RT in the treatment of cervical cancer. However, this evidence was limited by the imbalance among studies. Due to the encouraging efficacy and low toxicity, carboplatin is a suitable concurrent agent for patients with contraindications to cisplatin.
引用
- Xue R, Cai X, Xu H, et al. The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of cervical cancer: A meta-analysis. Gynecol Oncol. 2018. PMID: 29996970. doi:10.1016/j.ygyno.2018.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。